Hyphens Pharma International Limited, often referred to as Hyphens Pharma, is a prominent player in the pharmaceutical and healthcare industry, headquartered in Singapore (SG). Established in 2001, the company has made significant strides in providing innovative healthcare solutions across Asia, with a focus on specialty pharmaceuticals and consumer health products. Hyphens Pharma is renowned for its unique portfolio, which includes prescription medicines, over-the-counter products, and nutraceuticals. The company distinguishes itself through strategic partnerships and a commitment to quality, ensuring that its offerings meet the highest standards of efficacy and safety. With a strong market position, Hyphens Pharma has achieved notable milestones, including expanding its operational reach and enhancing its product line to cater to diverse healthcare needs.
How does Hyphens Pharma International Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Hyphens Pharma International Limited's score of 28 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Hyphens Pharma International Limited reported total carbon emissions of approximately 470,200 kg CO2e, comprising 26,200 kg CO2e from Scope 1 and 444,000 kg CO2e from Scope 2 emissions. This marks an increase from 2023, when the company recorded total emissions of about 408,700 kg CO2e, with Scope 1 emissions at 10,700 kg CO2e and Scope 2 emissions at 398,000 kg CO2e. Hyphens Pharma has not disclosed any Scope 3 emissions data, and there are currently no specific reduction targets or climate pledges outlined in their reports. The company does not inherit emissions data from a parent organization, indicating that all reported figures are self-contained. The emissions intensity for Hyphens Pharma is approximately 0.0024 tCO2e per million USD in revenue, reflecting their operational efficiency in relation to carbon output. As the company continues to navigate its environmental impact, further commitments and reduction strategies may be anticipated in future disclosures.
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 10,700 | 00,000 |
| Scope 2 | 398,000 | 000,000 |
| Scope 3 | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hyphens Pharma International Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.